Celyad Oncology Sa Stock Market Value
| CLYYF Stock | USD 0.15 0.00 0.00% |
| Symbol | Celyad |
Celyad Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Celyad Oncology's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Celyad Oncology.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Celyad Oncology on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Celyad Oncology SA or generate 0.0% return on investment in Celyad Oncology over 90 days. Celyad Oncology is related to or competes with Molecular Partners, XORTX Therapeutics, Nutriband, ZyVersa Therapeutics, Allarity Therapeutics, Aditxt, and Palisade Bio. Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric ant... More
Celyad Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Celyad Oncology's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Celyad Oncology SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 16.67 |
Celyad Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celyad Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Celyad Oncology's standard deviation. In reality, there are many statistical measures that can use Celyad Oncology historical prices to predict the future Celyad Oncology's volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (0.44) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | (1.48) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Celyad Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Celyad Oncology February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (1.47) | |||
| Mean Deviation | 0.7836 | |||
| Coefficient Of Variation | (588.10) | |||
| Standard Deviation | 2.38 | |||
| Variance | 5.65 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.44) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | (1.48) | |||
| Maximum Drawdown | 16.67 | |||
| Skewness | (6.13) | |||
| Kurtosis | 38.36 |
Celyad Oncology SA Backtested Returns
Celyad Oncology SA secures Sharpe Ratio (or Efficiency) of -0.17, which signifies that the company had a -0.17 % return per unit of risk over the last 3 months. Celyad Oncology SA exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Celyad Oncology's Standard Deviation of 2.38, mean deviation of 0.7836, and Risk Adjusted Performance of (0.13) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Celyad Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Celyad Oncology is expected to be smaller as well. At this point, Celyad Oncology SA has a negative expected return of -0.42%. Please make sure to confirm Celyad Oncology's standard deviation and skewness , to decide if Celyad Oncology SA performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Celyad Oncology SA has no correlation between past and present. Overlapping area represents the amount of predictability between Celyad Oncology time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Celyad Oncology SA price movement. The serial correlation of 0.0 indicates that just 0.0% of current Celyad Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Celyad Pink Sheet
Celyad Oncology financial ratios help investors to determine whether Celyad Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celyad with respect to the benefits of owning Celyad Oncology security.